Effect of Colchicine on TIMI frame count in ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention

Objective: There are historically evidence about the effect of inflammation process in pathophysiology of patients with ST-segment elevation myocardial infarction (STEMI). Colchicine is a known drug, which had different beneficial effects like anti-inflammatory feature and safety in cardiovascular patients. In this study, we aimed to evaluate the effect of colchicine on TIMI frame count in patients with STEMI undergoing primary percutaneous coronary intervention (PPCI).Methods & Materials: This was a two-center, prospective, triple-blinded, placebo-controlled clinical trial study, performed in two primary percutaneous coronary intervention referral hospitals, Imam Reza and Qaem in Mashhad, Iran. Sixty atients with anterior STEMI were randomly assigned to two groups (Colchicine, 2mg, orally and placebo group). Then patients underwent PPCI. The primary outcome parameter was final corrected thrombolysis in myocardial infarction frame count (cTFC) and secondary outcome was ST elevation resolution in EKG leads after angioplasty. After collecting data, it was categorized and analyzed by SPSS software version 16. Results: Of seventy-eight recruited patients, 69 patients ellocated and 60 patients were included in the final analysis (30 in the colchicine group and 30 controls). Forty-eight subjects were male (80%) and 12 subjects were female (20%). There was no significant difference in mean of Post-stenting cTFC in colchicine group was 24.27± 9.79 and in placebo group was 23.80± 11.92 (P=0.86). This was also repeated for mean of final cTFC which was 22.07± 8.84 in colchicine group and 22.66± 10.62 in placebo group (P= 0.10). There was significant correlation between time of initiation of pain to device time and mean of Post-stenting cTFC (r=0.649, P<0.001), final cTFC (r=0.786, P<0.001) but not with indexed lead ST resolution (r=-0.190, P=0.313) and summed ST resolution (r=-0.020, P=0.915), in control group.Conclusion: Our findings is not remarkable in improvement of cTFC as an important angiographic index. However, it was shown that it could protect the delay in the time of to device for cTFC rather than placebo.

کلیدواژه ها:

Colchicine ، corrected thrombolysis in myocardial infarction frame count ، STEMI